Myriad Genetics, Inc.

NASDAQ:MYGN

Medical - Diagnostics & Research

Healthcare
$5.53 +3.20%

+$0.14 today

Market cap
$530.45M
Beta
1.64
P/E (TTM)
-1.1
EPS (TTM)
-$4.27
52W Low $3.53High $8.59

Volume 1.26M

Average 1.81M

MYGN Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Myriad Genetics, Inc.NASDAQ: MYGN

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q1 FY2026 capital expenditures of $5.4M (cash outflow) fell 34.9% year over year, behind the -21.1% change in trailing-twelve-month capital expenditures. Sequentially, it rose 14.9% from the prior quarter. Over 3 fiscal years it compounded at -29.9% a year.

Context

  • Capital expenditures amounted to 1.9% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -34.9% toward the trailing-twelve-month pace of -21.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.4M+14.9% QoQ
Last fiscal yearDec 2025
-$15.6M-47.5% YoY
LTMMar 2026
-$23.2M-21.1% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.9%——
1 year-47.5%——
3-year CAGR-29.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(15.6M) USD
Year-over-year change
+47.5%

Capital Expenditures vs competitors

How MYGN compares with its peers on the latest reported figures

  • MYGN's LTM Mar 2026 capital expenditures of $23.2M is the 5th largest of the 10 companies compared; the peer median is $23.06M.
  • Its year-over-year change of -21.1% is the 8th highest of 9, against a peer median of +32.8%.
  • Capital expenditures amounts to 2.8% of revenue for MYGN, versus a peer median of 5.8%.
MYGN Competitors Peer median
Capital Expenditures for MYGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QGENQiagen N.V.LTM Jun 2026$206.77M +15.7%+10.4%9.8%
NTRANatera, Inc.LTM Jun 2026$156.54M +90.6%+30.6%5.8%
GHGuardant Health, Inc.LTM Sep 2026$58.67M +49.2%-14.6%4.6%
NEONeoGenomics, Inc.LTM Jun 2026$29.4M -11.5%-4.4%3.8%
MYGNMyriad Genetics, Inc.LTM Mar 2026$23.2M -21.1%-29.9%2.8%
FLGTFulgent Genetics, Inc.LTM Mar 2026$23.06M -43.7%+6.3%7.2%
VCYTVeracyte, Inc.LTM Jun 2026$12.93M +36.2%+4.2%2.3%
BLLNBillionToOne, Inc.LTM Jun 2026$12.18M ——3.1%
PSNLPersonalis, Inc.LTM Mar 2026$5.19M +29.3%-55.1%8.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$3.49M +602.4%-9.8%179.1%
Peer median (excluding MYGN) $23.06M+32.8%-0.1%5.8%

Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.2M)(112M)(263.3M)(127.3M)(365.9M)
Depreciation & Amortization62.8M52.7M61.9M61.2M53.7M
Deferred Income Tax(34.7M)(31.9M)(600K)(300K)(32.4M)
Stock-Based Compensation36.3M38.1M40.7M49.8M35.2M
Change in Working Capital120.8M(83.5M)27M(54.4M)(19.3M)
Accounts Receivables(8.8M)7.7M3.8M(8.7M)6.2M
Inventory1.6M(2.9M)(1.8M)(6.2M)(3.2M)
Accounts Payables9.2M(3.5M)(3.7M)4.7M(1.4M)
Other Working Capital118.8M(84.8M)28.7M(44.2M)(20.9M)
Other Non-Cash Items(139.4M)30.3M23.4M62.3M21.1M
Operating Cash Flow18.6M(106.3M)(110.9M)(8.7M)1.8M
Capital Expenditures(18M)(45.3M)(73.3M)(29.7M)(15.6M)
Acquisitions (Net)379.1M(57.2M)08.8M0
Purchases of Investments(147.8M)(103.2M)000
Sales of Investments61.1M128.2M105.2M9M0
Other Investing Activities00000
Investing Cash Flow274.4M(77.5M)31.9M(11.9M)(27.4M)
Debt Repayment(226.4M)—39.8M100K75.9M
Common Stock Issued00117.6M03.3M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities75.8M(8M)(4.5M)(7.5M)(15M)
Financing Cash Flow(150.6M)(8M)152.9M(7.4M)64.2M
Effect of Forex Changes(600K)(600K)600K(1M)800K
Net Change in Cash141.8M(192.4M)74.5M(29M)39.4M
Free Cash Flow600K(151.6M)(184.2M)(38.4M)(13.8M)

Myriad Genetics, Inc.

NASDAQ:MYGN

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.